Optaflu (influenza vaccine (surface antigen, inactivated, prepared in cell cultures))
- Region
- 🇪🇺 EU
- Active substance
- influenza vaccine (surface antigen, inactivated, prepared in cell cultures)
- Company
- Seqirus GmbH
- Status
- Expired
- Therapeutic area
- Influenza, Human; Immunization
- EU approval
- Fri 01 Jun 2007
- Application
- EMEA/H/C/000758
- ATC
- J07BB02
- Official record
- www.ema.europa.eu
Indication
Prophylaxis of influenza for adults, especially in those who run an increased risk of associated complications. Optaflu should be used in accordance to official guidance.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Aujemflu Authorised · Seqirus Netherlands B.V.
- 🇪🇺 Fluad Authorised · Seqirus Netherlands B.V.
- 🇪🇺 Flucelvax Authorised · Seqirus Netherlands B.V.
- 🇪🇺 Flucelvax Tetra Withdrawn · Seqirus Netherlands B.V.
- 🇪🇺 Fluad Tetra Withdrawn · Seqirus Netherlands B.V.
Follow Optaflu
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.